Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders

Close metadata

Recommended articles:

Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74

Features of the clinical picture of affective disorders in women during the menopausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79

Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30

Posttraumatic stress disorder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68

Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137

Trait and state anxiety, symptoms of insomnia and their influence on daytime functioning in adolescent girls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):66-71

Sleep disorders and oncological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Oral sedation in pediatric outpatient dentistry. Stomatology. 2024;(3):42-49

The article reflects the results of a number of studies that demonstrate the therapeutic effectiveness of Recognan (citicoline) in anxiety-depressive and asthenic disorders against the background of somatic and neurological diseases, in the correction of post-stroke depression. Recent experimental animal studies prove the effect of citicoline on anxiety and depression. In the complex effect, Recognan potentiates the main pharmacological effect of antidepressants and anxiolytics. In some studies, a dose-dependent change in animal behavior has been observed in response to the analgesic and antidepressant effects of citicoline. The effectiveness of citicoline in combination with transcranial direct current stimulation in the treatment of depression has been shown. The analysis of these research materials allows us to recommend Recognan in the complex therapy of asthenic and anxiety-depressive disorders in response to such pathological conditions as anxiety, asthenia, depression.

Keywords:

citicoline

Recognan

asthenia

anxiety

depression

Authors:

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

SPIN RSCI: 5300-4282
ORCID: 0000-0003-3726-0730

Received:

10.04.2024

Accepted:

16.04.2024

List of references:

Amnzade A, Zarrindast MR, Khakpai F. Additive anxiolytic-like effect of citicoline and ACPA in the non-acute restraint stress (NARS) and acute restraint stress (ARS) mice. Physiol Behav. 2024;277:114506. https://doi.org/10.1016/j.physbeh.2024.114506
Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52(suppl 2):S1-62.
Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. Eur J Pharmacol. 2016;789:275-279. https://doi.org/10.1016/j.ejphar.2016.07.048
Secades JJ, Gareri P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(supll 5):S1-89. https://doi.org/10.33588/rn.75S05.2022311
Secades JJ, Trimmel H, Salazar B, González JA. Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis. Life. 2023;13:369. https://doi.org/10.3390/life13020369
Castagna A, Manzo C, Fabbo A, et al. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in older patients affected with Alzheimer’s disease. Clin Drug Invest. 2021;41(2):177-182. https://doi.org/10.1007/s40261-020-00996-2
Akhondzadeh S, Gerbarg PL, Brown RP. Nutrients for prevention and treatment of mental health disorders. Psych Clin North Am. 2013;36(1):25-36. https://doi.org/10.1016/j.psc.2012.12.003
Gareri P, Gallelli L, Cotroneo AM, et al. The art of safe and judicious deprescribing in an elderly patient: a case report. Geriatrics (Basel). 2020;5(3):57. https://doi.org/10.3390/geriatrics5030057
Nemkova SA, Semenov DV, Petrova EA, et al. Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):27-34. (In Russ.). https://doi.org/10.17116/jnevro201911907127
Nemkova SA, Semenov DV, Zavadenko NN, Vozvyshaeva MYu. Features of positive personality phenomena in patients with mild cognitive impairment and asthenic syndrome treated with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(1):44-50. (In Russ.). https://doi.org/10.17116/jnevro202012001144
Nemkova SA, Semenov DV, Zavadenko NN, Vozvyshaeva MYu. The influence of the drug recognan (citicoline) on neurodynamic characteristics of mental activity in patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):43-46. (In Russ.). https://doi.org/10.17116/jnevro202112101143
Nemkova SA, Semenov DV, Petrova EA, et al. The effect of the use of the drug Recognan (Citicoline) on the state of higher mental functions in patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):51-57. (In Russ.). https://doi.org/10.17116/jnevro202112109151
Chutko LS, Surushkina SY, Yakovenko EA, et al. Impairments of cognitive control in patients with somatoform disorders and their treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):32-37. (In Russ.). https://doi.org/10.17116/jnevro201911904132
Shavlovskaya OA, Bokova IA. Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):57-62. (In Russ.). https://doi.org/10.17116/jnevro202412403157
Shuteeva TV. The use of neipilept in treatment of asthenic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(2):81-84. (In Russ.). https://doi.org/10.17116/jnevro20181182181-84
Corallo F, Scarfì C, Arcadi FA, et al. Role of functional pharmacological therapy in post-stroke depression: a narrative review. J Int Med Res. 2020;48(10):300060520950557. https://doi.org/10.1177/0300060520950557
Arcadi FA, Corallo F, Torrisi M, et al. Role of citicoline and choline in the treatment of post-stroke depression: an exploratory study. J Int Med Res. 2021;49(11):3000605211055036. https://doi.org/10.1177/03000605211055036
Shavlovskaya OA, Bokova IA. Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):22-28. (In Russ). https://doi.org/10.17116/jnevro202312311122
Amanzade A, Khakpai F, Zarrindast M-R. Synergistic antidepressant-like effect of citicoline and CB 1 agonist in male mice. Psychopharmacol (Berl). 2024;241(4):753-766. https://doi.org/10.1007/s00213-023-06507-3
Nejati S, Khakpai F, Zarrindast MR. Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: An isobologram analysis. Brain Res. 2020;1734:146701. https://doi.org/10.1016/j.brainres.2020.146701
Nemkova SA, Semenov DV, Petrova EA, et al. Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):11-18. (In Russ.). https://doi.org/10.17116/jnevro201811812111
Lipovka VP, Ivanov EA, Munika AA. Psychoemotional state of military personnel participating in the exercises. Actual Problems of Physical and Special Training of Law Enforcement Agencies. 2023;1:149-153. (In Russ).
Shayan E, Maheri F, Aflaki F, et al. Synergistic effects of citicoline and silymarin nanomicelles in restraint stress-exposed mice. Behav Brain Res. 2024;464:114929. https://doi.org/10.1016/j.bbr.2024.114929
Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;9(9):CD011612. https://doi.org/10.1002/14651858.CD011612.pub3
Khakpai F, Zarrindast MR. The effect of nicotine on antidepressant and anxiolytic responses induced by citalopram and citicoline in mice. Acta Neurobiol Exp (Wars). 2023;83(2):194-202. https://doi.org/10.55782/ane-2023-017
Khakpai F, Ramezanikhah M, Valizadegan F, Zarrindast M-R. Synergistic effect between imipramine and citicoline upon induction of analgesic and antidepressant effects in mice. Neurosci Let. 2021;760:136095. https://doi.org/10.1016/j.neulet.2021.136095
Roohi-Azizi M, Arabzadeh S, Amidfar M, et al. Citicoline combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2017;40(1):5. https://doi.org/10.1097/WNF.0000000000000185
Hart T, Benn EK, Bagiella E, et al. Early trajectory of psychiatric symptoms after traumatic brain injury: relationship to patient and injury characteristics. J Neurotrauma. 2014;31(7):610-617. https://doi.org/10.1089/neu.2013.3041
Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury. JAMA. 2012;308(19):1993. https://doi.org/10.1001/jama.2012.13256
Payamshad S, Khakpai F, Nasehi M, Zarrindast M-R. Effect of citicoline and transcranial direct current stimulation on depressive-like behaviors in mice & quot. Behav Brain Res. 2023;450:114495. https://doi.org/10.1016/j.bbr.2023.114495

Close metadata